- Home
- SBRA vs ALKS Comparison
SBRA vs ALKS Comparison
Compare SBRA & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | ALKS |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.6B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | SBRA | ALKS |
|---|---|---|
| Price | $19.23 | $33.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $20.75 | ★ $42.85 |
| AVG Volume (30 Days) | ★ 2.5M | 2.2M |
| Earning Date | 02-12-2026 | 02-13-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 78.50 | 2.44 |
| EPS | 0.73 | ★ 2.02 |
| Revenue | $747,056,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $5.71 | $23.22 |
| P/E Ratio | $25.28 | ★ $16.92 |
| Revenue Growth | ★ 9.34 | 1.08 |
| 52 Week Low | $15.60 | $25.17 |
| 52 Week High | $19.97 | $36.45 |
Technical Indicators
Market Signals| Indicator | SBRA | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 58.04 |
| Support Level | $17.81 | $33.43 |
| Resistance Level | $18.90 | $35.30 |
| Average True Range (ATR) | 0.41 | 1.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 81.27 | 54.22 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.